Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 13, 2010

View Archived Issues

Daiichi Sankyo claims new ligands of voltage-dependent calcium channel subunit alpha2-delta

University of Ulsan identifies new anticancer prodrugs

Phase III panitumumab trial in head and neck cancer does not meet primary endpoint

NeoStem and Schepens Eye Research Institute enter agreement for retinal diseases

Ustekinumab yields sustained response in phase II and III trials in plaque psoriasis

Israeli scientists describe new muscarinic acetylcholine M1 receptor modulators

Italian researchers present new NS5B inhibitors

Bristol-Myers Squibb claims new S1P1 receptor agonists

PregLem inlicenses bentamapimod from Merck Serono for postoperative adhesions and endometriosis

Abobotulinumtoxin A rapidly reduces glabellar lines in phase III trials

Cannabinoids show promise in models of inflammation and bone loss

New clindamycin/tretinoin gel more effective than constituents in treating acne

SLC40A1 is a marker of breast cancer prognosis

Onabotulinumtoxin A is safe and efficacious in women with vertical lip columns

Vyteris reports phase II data on transdermal patch for female infertility

Agile Therapeutics begins phase III trial of contraceptive patch AG-200-15

Astex and Multiple Myeloma Research Consortium start phase II AT-7519 trial

FDA advisory committee votes in favor of ezogabine

Labopharm launches Oleptro in U.S. for major depressive disorder

Mologen reports results for first half of 2010

PMX-60056 shows promise as heparin activity-reversing agent in phase Ib/II trial

PSI-7977 receives FDA fast track status for chronic HCV infection

FDA grants orphan status to becaplermin in osteochondritis dissecans

FDA warns of risk of aseptic meningitis associated with Lamictal use

European Commission grants orphan status to bosutinib in CML

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 17, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...